- Home
- GPRK vs AVTX Comparison
GPRK vs AVTX Comparison
Compare GPRK & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPRK | AVTX |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.8M | 339.9M |
| IPO Year | 2009 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GPRK | AVTX |
|---|---|---|
| Price | $9.23 | $13.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $8.50 | ★ $36.80 |
| AVG Volume (30 Days) | ★ 1.4M | 778.2K |
| Earning Date | 05-06-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | $39.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $5.66 | $3.39 |
| 52 Week High | $10.34 | $20.72 |
Technical Indicators
Market Signals| Indicator | GPRK | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 38.73 |
| Support Level | $7.84 | $13.45 |
| Resistance Level | $10.34 | $16.40 |
| Average True Range (ATR) | 0.41 | 1.05 |
| MACD | -0.00 | -0.32 |
| Stochastic Oscillator | 47.03 | 18.41 |
Price Performance
Historical ComparisonAbout GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).